BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 18, 2011
 |  BioCentury  |  Strategy

mAbs are icing on the cake

Antibody deal with Abbott boosts Biotest while it focuses on plasma proteins

Biotest AG has returned to its roots in plasma proteins. After selling off its tools and diagnostics businesses, the company is looking to grow by increasing its plasma protein product offerings and expanding its global presence. Along the way, it plans to opportunistically outlicense a small portfolio of mAbs after advancing them through Phase II testing.

Biotest did its first such deal last month by partnering its BT-061 with Abbott Laboratories for $85 million up front.

Over Biotest's 65-year history, the company has focused on hematology products including therapeutics derived from purified plasma proteins and diagnostics that ensure tissue and blood donor matching.

The company formed a biotherapeutics division in 2005 based on three mAbs that had been discovered by its Diaclone SAS subsidiary. While the mAbs had been used for diagnostic purposes, preclinical studies suggested they had potential to treat autoimmune diseases and cancer, according to spokesperson Monika Buttkereit.

In 2007, the company decided to get out of the diagnostics business altogether.

Read the full 808 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >